Pre-medication With Alfentanil vs Placebo During ECT

• Status: Completed
• Trial end date: 2020-02-17
• Target enrollment: 0
• Participant gender: All

Summary

Hemodynamic changes associated with the conduct of electroconvulsive therapy may be minimized with the administration of alfentanil as part of their anesthetic regimen. This study proposes to compare the effects in a blinded fashion. Currently alfentanil is an FDA approved drug used on a daily basis by anesthesiologists on other surgeries so this is not a new indication.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Treatments: Alfentanil

Criteria

Inclusion Criteria:

• Age > /=18 years

• Males or females

• Anticipating electroconvulsive therapy to treat refractory depressive disorder

Exclusion Criteria:

• Under the age of 18

• Allergy to alfentanil

• Allergy to other standard anesthetic medications utilized in the course of ECT (glycopyrrolate, methohexital, and succinylcholine)

• History of malignant hyperthermia

• History of severe airway obstruction, bronchospasm or laryngospasm

• History of recent myocardial infarction, ventricular arrhythmia

• Adverse reaction to ECT requiring premedication with lidocaine or atropine

• Non-English speaking

• Patients unable to consent for themselves

• Current pregnancy